CorMedix (CRMD) Income from Continuing Operations (2010 - 2026)
CorMedix (CRMD) posted Income from Continuing Operations of 11776859.0 for Q4 2025, down 110.85% sequentially from 108562980.0 in Q3 2025, and down 187.47% YoY from 13464424.0 in Q4 2024.
CorMedix (CRMD) Income from Continuing Operations (2010 - 2026) Analysis & Trends
CorMedix has reported Income from Continuing Operations for 16 years, with the latest figure at 11776859.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 187.47% year-over-year to 11776859.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 137258000.0 (up 865.52% YoY) and the FY2025 annual result came in at 137258000.0, up 865.52% from the prior year.
- Income from Continuing Operations retreated to 11776859.0 in Q4 2025 per CRMD's latest filing, from 108562980.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 108562980.0 in Q3 2025 and troughed at 17255239.0 in Q1 2021.
- A 5-year average of 101696.95 and a median of 8389158.5 in 2021 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2021 and 2025: Income from Continuing Operations tumbled 199.88% in 2021, then soared 4002.28% in 2025.
- Over 5 years, Income from Continuing Operations stood at 9667173.0 in 2021, then gained by 15.08% to 8208951.0 in 2022, then slumped by 79.73% to 14754029.0 in 2023, then jumped by 191.26% to 13464424.0 in 2024, then sank by 187.47% to 11776859.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 11776859.0, 108562980.0, and 19827981.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | 25.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.99 Mn |
| Dec 31, 2025 | -11.78 Mn |
| Sep 30, 2025 | 108.56 Mn |
| Jun 30, 2025 | 19.83 Mn |
| Mar 31, 2025 | 20.64 Mn |
| Dec 31, 2024 | 13.46 Mn |
| Sep 30, 2024 | -2.78 Mn |
| Jun 30, 2024 | -14.15 Mn |
| Mar 31, 2024 | -14.47 Mn |
| Dec 31, 2023 | -14.75 Mn |
| Sep 30, 2023 | -9.74 Mn |
| Jun 30, 2023 | -11.27 Mn |
| Mar 31, 2023 | -10.57 Mn |
| Dec 31, 2022 | -8.21 Mn |
| Sep 30, 2022 | -6.85 Mn |
| Jun 30, 2022 | -7.60 Mn |
| Mar 31, 2022 | -8.16 Mn |
| Dec 31, 2021 | -9.67 Mn |
| Sep 30, 2021 | -8.57 Mn |
| Jun 30, 2021 | -4.63 Mn |